Skip to content

Science

Better cancer immunotherapies for patients start
with better antigen selection

At Genocea, it is our mission to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor.

In addition to our two clinical-stage oncology programs, GEN-009 and GEN-011, we are applying ATLAS to antigen discovery in multiple other disease settings.

Click to toggle:
ATLAS
Inhibigens

Unique and proprietary antigen discovery platform

ATLAS™ is a unique bioassay that enables a superior, patient biology-driven approach to identify targets of protective T cell responses. ATLAS zeroes in on only those surface-presented antigens that trigger anti-tumor T cell responses. Learn more about how ATLAS works to improve immunotherapies below.

What is ATLAS?

Pushing Boundaries

How ATLAS Works

Inhibigen: suppressesanti-tumor T cell responses Stimulatory antigen: elicitsanti-tumor T cell response Autologousdendritic cell AutologousT cell Blood sample Bacterial vectors expressing each candidate Tumor biopsy NGS analysis Uniqueplasmidsforevery candidate antigen

ATLAS antigen selection: our foundation

Foundation for effective immunotherapies
  • Included: Antigens relevant to both disease and patient immune system
  • Confirms antigens that are surface-presented and drive anti-tumor T cell responses

  • Excluded: Inhibigens, uniquely identified by ATLAS
  • CD4+ and CD8+ T cells responding to Inhibigens can promote tumor growth and compete with immunotherapy anti-tumor effects
Comprehensive
  • For any patient, any antigen type, any disease, and both CD4+ and CD8+ T cells
Scalable
  • ATLAS is a highly industrialized platform
Well-protected
  • Global patent families protect ATLAS into 2030s

Inhibigens™ – Identified Solely Through ATLAS

ATLAS is the only technology that can identify pro-tumor inhibitory antigens, or InhibigensTM, which subvert anti-tumor immune responses in the context of cancer immunotherapy. A growing body of foundational research led by the Genocea team has revealed the responses to Inhibigens enhance tumor growth and undermine otherwise effective immunotherapies.

inhibigens-image

 

Explore more information on this breakthrough research below:

Posters, Presentations, Publications and Videos

All Resources
ATLAS
Inhibigens
GEN-009
GEN-011
Infectious Disease
2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
ATLAS drives Genocea’s emerging immunotherapy pipeline of clinical stage programs. Learn more about our ATLAS-driven pipeline.